Introduction
Due to the random rearrangements of genes encoding T and B-lymphocyte antigenreceptors, a significant number of autospecific and potentially autoreactive lymphocytes develop in primary lymphoid organs [1] [2] [3] . Central tolerance (i.e. induced in primary lymphoid organs) eliminates (by deletion) or functionally inactivates (by induction of anergy) such dangerous lymphocytes. In absence of central tolerance-induction, a strongly self-reactive T cell repertoire develops 4, 5 . However, when central tolerance is partially defective, selftolerance can be maintained by peripheral mechanisms [6] [7] [8] . Several types of peripheral tolerance mechanisms control lymphocytes having escaped central-tolerance and are known to play a crucial role in preventing autoimmunity (for reviews see refs. 6, 9 ).
One of these peripheral tolerance mechanisms was discovered using the day 3 thymectomy model of multi-organ autoimmunity in mice 10 . The pathology can be prevented by injection of CD4 + CD25 + lymphocytes, which appear after day 3 of life in the peripheral lymphoid organs of normal mice. CD4 + CD25 + regulatory T cells do not only inhibit autoimmunity; they can also inhibit experimental inflammatory bowel disease induced by injection of CD4 + CD45RB high cells into immunodeficient SCID mice or RAG-deficient animals 11 .
Moreover, they contribute to the fine control of immunity to infectious agents such as parasites and viruses 12, 13 . An undesired side-effect of the activity of CD4 + CD25 + regulatory T lymphocytes is the occasional incapacity of the immune system to eliminate tumor cells 14, 15 .
Therefore, regulatory T lymphocytes play a crucial role in the pathophysiological maintenance of immunological tolerance (reviewed in refs. 11, 16, 17, 18 ).
Natural (i.e. thymus-derived) CD4 + CD25 + regulatory T cells can induce transplantationtolerance in mice. Lethal graft-versus-host disease (GvHD) can be significantly reduced by injection of freshly isolated or ex vivo cultured regulatory T cells [19] [20] [21] [22] . In one report, freshly isolated CD4 + CD25 + regulatory T cells from naive animals were shown to induce limited tolerance to minor-histocompatibility-antigen disparate skin grafts 23 . Intrathymic injection of donor-strain antigen results in a tolerant state which was shown to be due to development of CD4 + CD25 + regulatory thymocytes 24 .
Regulatory T cells with a CD4 + CD25 + phenotype are also known to be involved in experimental systems in which tolerance to alloantigens is induced in vivo with antibodies to T cell surface-antigens (e.g. CD4, CD8, or CD154, refs. 23, 25, [26] [27] [28] [29] or with the active form of vitamin D3 and mycophenolate mofetil 30 . In these systems, however, it is not clear if thymusderived regulatory T cells (that can be found in naive animals) are involved or if these cells are induced in the periphery 31, 32 .
Like all other TCRαβ-expressing T lymphocytes, thymus-derived CD4 + CD25 + regulatory T lymphocytes are antigen-specific, at least during their activation-phase. These cells have been shown to proliferate in an antigen-specific manner in vivo [33] [34] [35] . Myelin basic proteinspecific CD4 + CD25 + regulatory T cells protect better against experimental autoimmune encephalomyelitis than regulatory T cells with a restricted (but non-myelin basic proteinspecific) TCR-repertoire 36 . Regulatory T cells activated in vitro with host-type APC inhibit GvHD more potently than cells activated with third-party APC 21, 22 . Also experimentally induced CD4 + CD25 + regulatory T cells act in a specific manner and protect target but not third-party allografts 27, 29 . In vitro, however, CD4 + CD25 + regulatory T cells only require interaction with specific MHC/peptide complexes during their activation phase. Once activated, their suppressor effector function is completely non antigen-specific 37 . The antigen-specificity observed in vivo could therefore potentially be explained by the hypothesis that regulatory T cells are activated only in hosts presenting antigens for which they are specific. In mice in which these antigens are not expressed, the regulatory T cells are not activated and immunosuppression does not take place. supplemented with 10% FCS, 2 mM L-glutamine, Penicillin, Streptomycin, 10 mM Hepes , 50 µM 2-ME, 1 mM non essential amino acids, 1 mM sodium pyruvate and 100 U/ml IL-2 (supernatant of PMA-stimulated EL4.IL-2 cells; ATCC, Manassas, VA). At day 7, 100µl of fresh medium was added and cells were cultured for another 7 days.
Bone marrow chimeras
Bone marrow from femurs and tibias was collected in DMEM (Eurobio, Les Ulis, France)
supplemented with 10% FCS, 2 mM L-glutamine, Penicillin, Streptomycin. Single cell suspensions were washed in complete medium. Thy1 + and NK1.1 + cells were eliminated using AT83 and PK136 Abs, respectively, and rabbit complement (Saxon Europe, Suffolk, UK). 5x10 6 cells from each donor were then injected i.v. into γ-irradiated hosts (850 Rad, 137 Cs source, 630 Rad/minute) that were kept on antibiotic-containing water (0.28% pediatric suspension of Bactrim, Roche, Basel, Switzerland) for the complete duration of the experiment. Effector and/or regulatory T cells were co-injected with bone-marrow preparations.
FACS analysis
For analysis of bone-marrow from femurs and tibias, mice were sacrificed 15 days after bone-marrow and T cell transfer. For PBMC-analysis, blood samples were taken at indicated In these experiments, bone-marrow engraftment was analyzed after 2 weeks. To assess if the tolerance was durable, we reconstituted lethally irradiated B6 mice with syngeneic and semi-allogeneic bone-marrow, co-injected them with B6 splenocytes and preactivated B6 regulatory T cells, and analyzed peripheral blood mononuclear cells from 1 to 11 weeks postreconstitution. Figure 2C shows that the tolerance was durable: up to 11 weeks after transfer no signs of rejection were observed at regulatory T cell/splenocyte ratios of 2 and 10. At a regulatory T cell/splenocyte ratio of 1:2 levels of protection were quite variable among the four animals analyzed. Interestingly, once established, the percentage of allogeneic cells in PBMC did not significantly change during the period in which the animals were analyzed.
Results

Ex vivo
Therefore, even partial protection appears to be stable in time. We are currently investigating the underlying mechanisms. The results in figure 3A show that B6D2F1 bone marrow was more efficiently protected than B6CBAF1 cells, most notably at lower regulatory T cell to splenocyte ratios.
Since this specific protection might hypothetically be due to differences in the kinetics and/or potency of rejection of the two types of bone-marrow, we also performed the reciprocal experiment and tested if B6 regulatory T cells activated in vitro with B6CBAF1
APC acted in a specific manner (Fig. 3B) . At a regulatory T cell to splenocyte ratio of 0.5, B6CBAF1 bone marrow was more efficiently protected than B6D2F1 cells. When using higher regulatory T cell to splenocyte ratios the specificity was lost.
Regulatory T cells protect target bone marrow while allowing third party alloreactivity to develop simultaneously
Since the observed specificity in the protection of allogeneic bone-marrow might be due to several factors other than specificity in the effector function of regulatory T cells (e.g. differential survival, homeostatic expansion, or activation in the distinct experimental mice),
we then tested if the specificity was maintained when both types of semi-allogeneic bone marrow (i.e. B6D2F1 and B6CBAF1) were transferred (together with syngeneic bone-marrow) into the same host. When the three types of bone-marrow were injected without effector T cells, practically equivalent percentages of syngeneic (B6) and the two types of allogeneic (B6D2F1 and B6CBAF1) cells were found in bone marrow two weeks later (Fig.   4A ). As shown in figures 4B (top) and 4C, addition of syngeneic effector splenocytes resulted in the clearance of both allogeneic populations, and regulatory T cells preactivated with B6D2F1 APC preferentially inhibited rejection of B6D2F1 (as compared to B6CBAF1) bone marrow, especially at lower regulatory to effector T cell ratios. At higher regulatory to effector T cell ratios, specificity was gradually lost, and cells of both semi-allogeneic origins were efficiently preserved.
Again, to exclude the hypothetical possibility that the observed specificity was due to immunopathology. All these models have in common that injection of T lymphocytes must be followed by homeostatic proliferation. In the colitis model, disease is induced in lymphopenic mice 11 . GvHD models rely on lethally irradiated recipients, which are therefore lymphopenic [19] [20] [21] 38 . The induction of transplantation-tolerance (GvHD or graft-rejection) with experimentally induced CD4 + CD25 + regulatory T cells has also been studied in lymphopenic mice 23, [25] [26] [27] [28] [29] . In the experimental models of autoimmunity induced by day 3 thymectomy or in nude mice, homeostatic expansion of injected T lymphocytes also certainly occurs 10 . Since regulatory T cells are known to regulate homeostatic expansion and to expand themselves in immunodeficient mice 39, 40 , it has been suggested that regulatory T cells could outcompete pathogenic T cells during the expansion-phase and thus inhibit immunopathology 41 . Such a scenario could also explain the regulatory T cell-induced tolerance we observed when mice were injected with only one type of allogeneic bone-marrow (target or third party). In experiments in which the mice were co-injected with two types of allogeneic bone-marrow, however, target bone marrow was preferentially protected (notably at low regulatory to effector T cell ratios). Therefore, in contrast to the abovementioned reports, in our system tolerance cannot be explained by differential homeostatic expansion of alloreactive versus innocuous regulatory T cells.
T-cell tolerance induced by CD4 + CD25 + regulatory T lymphocytes has never before been shown to be antigen-specific in the effector phase. In GvHD and transplantation models, tolerance was studied in separate hosts 21, 22, 27, 29 . Since homeostatic proliferation of regulatory T cells depends upon MHC class II expression 40 and potentially even upon interaction with specific antigen 33 , antigen-specificity in vivo may be due to lack of homeostatic proliferation in animals lacking the "target" tissue. In these models, antigen-specificity is probably also due to the absence of specific ligands capable of activating the suppressor-effector function of regulatory T-lymphocytes. These hypothetical explanations may also apply to the specific tolerance we observed when target and third party bone marrows were injected (together with splenocytes and regulatory T cells) into separate hosts. However, we also observed preferential protection of target bone marrow in mice in which third party cells were simultaneously rejected. One could argue that the specific protection was due to differences in the kinetics and/or potency of rejection of the two types of bone marrow but such objections can be ruled out since identical results were obtained in reciprocal experiments. Since target bone marrow was protected in these mice, regulatory T cells had clearly been activated, but protected third-party bone marrow much less efficiently. Therefore, our data directly show that CD4 + CD25 + regulatory T cells can act in an antigen-specific manner during their effector phase.
Several reason(s) could explain why protection is not entirely antigen-specific, especially at higher regulatory to effector T cell ratios. Since this lack of specificity was also observed in mice in which target bone-marrow was absent, regulatory T cells are sufficiently crossreactive with third-party antigens to cause partial protection. Such a cross-reactivity may in part be due to "indirect antigen presentation" by host-type MHC molecules that are expressed by both types of semi-allogeneic bone marrows. Direct cross-reactivity towards allogeneic MHC molecules most likely also plays an important role 3 . In contrast to the C57BL/6 hosts we used, both donor strains (B6D2F1 and B6CBAF1) present several mouse mammary tumor virus-encoded endogenous superantigens 42 . Therefore, superantigen-reactivity of injected regulatory T cells may cause very significant cross-reactivity. In the mice in which we injected both types of allogeneic bone-marrow a contribution of non antigen-specific "bystander" mechanisms formally cannot be excluded. In any case, our data directly indicate 
